February 27, 2020 / 7:27 AM / a month ago

BRIEF-Hikma Pharmaceutical Enters Into Agreement To Commercialise Ryaltris™

Feb 27 (Reuters) - Hikma Pharmaceuticals PLC:

* HIKMA ENTERS AGREEMENT TO COMMERCIALISE RYALTRIS™

* CO AND GLENMARK SPECIALTY S.A., UNIT OF GLENMARK PHARMACEUTICALS, ANNOUNCE SIGNING OF US LICENSE AGREEMENT TO COMMERCIALISE RYALTRIS

* UNDER TERMS, GLENMARK WILL BE RESPONSIBLE FOR CONTINUED DEVELOPMENT AND REGULATORY APPROVAL OF RYALTRIS™ BY US FOOD AND DRUG ADMINISTRATION

* HIKMA WILL BE RESPONSIBLE FOR COMMERCIALISATION OF RYALTRIS™ IN US FOLLOWING APPROVAL

* HIKMA WILL PROVIDE GLENMARK WITH AN UPFRONT PAYMENT, REGULATORY APPROVAL AND COMMERCIAL MILESTONE PAYMENTS AS WELL AS ROYALTIES

Source text for Eikon:

Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below